The subsequent Neo-Trio clinical trial of neoadjuvant anti-PD-1 (pembrolizumab) in sequence with or concurrent with dabrafenib/trametinib in resectable Stage III BRAFV600-mutant melanoma patients showed that the pathological response rate (pRR of 80%) and the pathological complete response rate (pCR of 50%) were highest in the concurrent triple arm [55]. Here, PDCD1 is linked to melanoma.